Clinical Trials on Stage III/IV Melanoma in Netherlands

Total 70 results

The Netherlands Cancer Institute

Recruiting

FMT to Convert Response to Immunotherapy

Melanoma Stage IV | Melanoma Stage III

Netherlands
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Radboud University Medical Center
Dutch Cancer Society

Completed

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Melanoma Stage III or IV

Netherlands
Radboud University Medical Center
Dutch Cancer Society

Completed

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Melanoma Stage III or IV

Netherlands
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

Stage III Skin Melanoma

Netherlands
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
Saint John's Cancer Institute
Melanoma Research Alliance

Terminated

Stage IV Surgery Versus Best Medical Therapy (STG4SURG)

Stage IV Resectable Melanoma

United States, Australia, Israel, Italy, Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
The Netherlands Cancer Institute
AstraZeneca

Unknown

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (Induction)

Stage III NSCLC

Netherlands
Maastricht Radiation Oncology
Amsterdam UMC, location VUmc

Completed

Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients (Cetuximab Zr89)

Stage IV Cancer

Netherlands
Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece
Radboud University Medical Center
Maastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaborators

Recruiting

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer (PROMOTE)

Endometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IV

Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...
UMC Utrecht

Completed

PDL-1 Targeting in Resectable Oesophageal Cancer (PERFECT)

Esophageal Cancer, Stage II | Esophageal Cancer Stage III

Netherlands
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Canadian Cancer... and other collaborators

Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)

Cutaneous Melanoma, Stage II

United States, Canada, United Kingdom, Australia, Italy, Sweden, Netherlands, New Zealand
The Netherlands Cancer Institute
Bristol-Myers Squibb

Terminated

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

NSCLC, Stage IV

Netherlands
The Netherlands Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib and Radiotherapy in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage III

Netherlands
University Hospital, Essen

Recruiting

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)

NSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIA

Belgium, Germany, Netherlands
Maastricht Radiation Oncology
Karolinska Institutet; KU Leuven; Maastricht University Medical Center; Catholic... and other collaborators

Withdrawn

Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) (ImmunoSABR)

NSCLC Stage IV | Limited Metastatic Disease

Netherlands
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
Maastricht Radiation Oncology

Not yet recruiting

Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer (Re-Induce 2)

Lung Cancer Stage IV

Netherlands
Maastricht University Medical Center
KU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaborators

Active, not recruiting

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)

NSCLC Stage IV | Metastatic Disease

Netherlands, Belgium, United Kingdom, Germany, France, Italy
Amsterdam UMC, location VUmc

Completed

Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) (COLONUT)

Stage IV Colorectal Cancer

Netherlands
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
UMC Utrecht

Unknown

MRI Optimization Study in Stage III NSCLC

Stage III Non-small Cell Lung Cancer

Netherlands
Maastricht University

Not yet recruiting

Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-II

Lung Cancer Stage I | Lung Cancer Stage II

Netherlands
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
Radboud University Medical Center

Terminated

Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy (IDEAL-VMAT)

Stage III Non-small Cell Lung Cancer | Individualized Radiation Dose Escalation

Netherlands
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)

Stage I-III Non-small Cell Lung Cancer

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)

Stage I-III Small Cell Lung Cancer

Netherlands
MicroPort CRM
Sorin CRM

Unknown

Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D (RESPOND-CRT)

Heart Failure NYHA Class III and Ambulatory IV

United States, Spain, United Kingdom, Germany, Italy, Australia, Netherlands, Portugal, France, Austria, Switzerland, Slovenia
The Netherlands Cancer Institute
Dutch Cancer Society

Terminated

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis (HALO)

Lung Metastases | Lung Cancer Stage I | Lung Cancer Stage II

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Stage IV (Oligo-metastases)

Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
Leiden University Medical Center
Jessa Hospital; The Netherlands Cancer Institute

Recruiting

Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy (Prediction)

Immunotherapy | Non Small Cell Lung Cancer Stage III

Netherlands, Belgium
Maastricht University Medical Center
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

NSCLC Stage IV | Brain Metastases, Adult

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Immutep S.A.S.

Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Adenocarcinoma Breast Stage IV

Netherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
Maastricht Radiation Oncology
Maastricht University Medical Center; Zuyderland Medical Centre

Completed

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Stage IV Non-small Cell Lung Cancer

Netherlands
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
UMC Utrecht
Center for Translational Molecular Medicine; Dutch Cancer Society; Vrienden UMC...

Recruiting

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (i-GO)

Breast Cancer | Breast Neoplasms | Metastatic Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Invasive Ductal Breast Cancer | Invasive Ductal Carcinoma of Female Breast | Adenocarcinoma Breast

Netherlands
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria

Clinical Trials on Stage III/IV Melanoma in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations